Results for tag: "Opioid Induced Constipation"

'''Opioid Induced Constipation (OIC) Market in Gastroenterology''' In the field of gastroenterology, opioid induced constipation (OIC) presents a common complication due to the use of opioid medications, which are often prescribed for pain management. Opioids, while providing relief from pain, simultaneously impede the motility of the gastrointestinal tract, leading to constipation. The market for treating OIC encompasses therapeutics designed to counteract the effects of opioids on the gut without compromising their analgesic efficacy. These treatments aim to improve patient quality of life by managing constipation symptoms, which often include abdominal pain, discomfort, and bloating. Pharmaceutical companies in this market have developed a variety of both prescription and over-the-counter remedies, ranging from laxatives to receptor-targeted therapies. The latter specifically addresses the enteric nervous system to reduce the constipating effects of opioids. Despite the existence of general constipation treatments, those developed for OIC are distinct, focusing on addressing the unique pathophysiology of opioid-related gastrointestinal effects. '''Companies in the OIC Market''' Several companies contribute to the market with their products and services. Among the prominent players are AstraZeneca, with their drug Movantik, and Takeda Pharmaceuticals, offering Amitiza. Mallinckrodt Pharmaceuticals is known for its drug Relistor. Pfizer has also made entries into the market with products targeting OIC. Allergan plays a role with its medication Linz Show Less Read more